Ro Research Lab retweeted
Insurance companies don’t make it easy to know where you stand with your GLP-1 coverage. So we did.
Our improved coverage checks and prior authorizations now live in one place on @ro - under your profile. See what's approved, what's in progress and what's next. No phone call required.
CVS just put a number on the GLP-1 break-even question. Using Aetna claims, they estimate that at ~$350/month, medical savings roughly offset the drug cost over 3 years.
Compared with matched non-users, GLP-1 users had:
- 10-12% fewer ER visits in years 1 and 2
- 14% lower odds of a major cardiovascular event
- 34-42% fewer hospitalizations among those still on the drug at year 3
At today’s employer prices (~$617-766/mo), plans saved $9,400 per person on medical but spent $13,300 more on Rx. Net: +$3,900.
The interesting part: cash prices (~$299-349) and Medicare’s $245 pilot price are already below CVS’s break-even. The barrier isn’t what these drugs can be sold for. It’s what employers are paying.
Family coverage now costs $28,303 a year (KFF). That’s why employers are dropping GLP-1s, not because the drugs don’t work. At ~$350/mo, they wouldn’t have to choose.
A few call outs: it's a CVS white paper... (insert disclaimers). Observational. Diabetes and obesity pooled. The year-3 group (n≈4,000) is people who stayed on, who may differ from those who stopped. And CVS has a seat at this negotiating table.
Affordability drives access.
The @RoResearchLab team breaking down just how hard it is to get insurance coverage for GLP1s.
We’ve invested a ton of time and energy here to fight for patients at each step but it’s often pushing a boulder up a hill.
I’m hopeful as the ROI improves (breadth of label expands, we get more data on benefits of GLP1s and reduction in hc costs are proven out), coverage will increase but I do think it will take a while. Unfortunately, we see large companies like Starbucks and entire states pulling coverage (it’s going in the wrong direction)!
Ro Research Lab retweeted
Comparative effectiveness of obesity treatments after initial therapy with semaglutide or tirzepatide:
Weight change after taking semaglutide or tirzepatide for 2 years was:
−10.9% with continuing the original medication
−16.0% with switching between semaglutide and tirzepatide
− 8.2% with switching to non- GLP-1 medication
−28.2% with undergoing Metabolic Surgery
− 4.0% with discontinuation of treatment
When GLP-1 fail: MBS is effective
@HamletGasoyan @Ali_Aminian_MD
#OW2026
thelancet.com/journals/eclin…
The @RoResearchLab, Dr. David Allison, and Dr. Dhurandhar developed a validated "Food Noise" scale. It measures: preoccupation, persistence, and dysphoria associated with food.
What's fascinating is that food noise for patients at lower BMIs were almost identical to higher BMIs.
It's another powerful reminder that we can't make assumptions on how someone is feeling on the inside based on how they may appear on the outside.
Ro Research Lab retweeted
Two new randomized trials of the potent GLP-1 drug retatrutide (aka "reta") showed marked relief of knee osteoarthritis. Prior work demonstrated that some of the GLP-1 benefit for knee osteoarthritis is independent of weight loss.
#AHA26 @NEJM
nejm.org/doi/full/10.1056/NE…
Ro Research Lab retweeted
Today there's a special outstanding @ScienceMagazine issue on GLP-1 drugs, obesity and adipose tissue
science.org/doi/10.1126/scie…
A thread below to summarize some of the papers











